Filing Flows › BioMarin Pharmaceutical (BMRN) › How it makes money
How BioMarin Pharmaceutical (BMRN) makes money
BioMarin Pharmaceutical (BMRN) made $1.0B of revenue in the third quarter 2026 (Q3 2026), +32% from a year earlier. Net product revenues brought in $1.0B (99%); Royalty and other revenues brought in $11.6M (1%).
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Net product revenues | $1.0B | 98.9% | +4% | +34% |
| ↳ VOXZOGO | $245M | 23.9% | -3% | +12% |
| ↳ VIMIZIM | $216M | 21.1% | +11% | +18% |
| ↳ GALAFOLD | $152M | 14.8% | +44% | — |
| ↳ PALYNZIQ | $111M | 10.8% | -18% | +2% |
| ↳ NAGLAZYME | $108M | 10.5% | -20% | -12% |
| ↳ ALDURAZYME | $56.6M | 5.5% | +30% | +5% |
| ↳ BRINEURA | $52.7M | 5.1% | +3% | +10% |
| ↳ POMBILITI + OPFOLDA | $48.6M | 4.7% | +61% | — |
| Royalty and other revenues | $11.6M | 1.1% | +118% | -25% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $1.0B | 100.0% |
| Operating cash flow | $188M | 18.4% |
| Free cash flow | $160M | 15.6% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $1.0B | +32% |
| Q2 2026 | $990M | +20% |
| Q1 2026 | $766M | +3% |
| Q4 2025 | $875M | +17% |
| Q3 2025 | $776M | +4% |
| Q2 2025 | $825M | +16% |
| Q1 2025 | $745M | +15% |
From BioMarin Pharmaceutical's 10-Q filed Nov 3, 2026 (on EDGAR).
Questions
How does BioMarin Pharmaceutical make money?
BioMarin Pharmaceutical (BMRN) made $1.0B of revenue in the third quarter 2026 (Q3 2026), +32% from a year earlier. Net product revenues brought in $1.0B (99%); Royalty and other revenues brought in $11.6M (1%).
What is BioMarin Pharmaceutical's biggest business?
Net product revenues: $1.0B in the third quarter 2026, 99% of revenue, +34% from a year earlier.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.